Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance

Ann Oncol. 2004 Jan;15(1):173-4. doi: 10.1093/annonc/mdh006.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / pathology
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Camptothecin / administration & dosage
  • Camptothecin / analogs & derivatives*
  • Disease Progression
  • Docetaxel
  • Drug Resistance, Neoplasm*
  • ErbB Receptors / drug effects
  • Gefitinib
  • Humans
  • Irinotecan
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / pathology
  • Male
  • Neoplasm Metastasis / drug therapy
  • Neoplasm Recurrence, Local
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Quinazolines / administration & dosage
  • Retreatment
  • Taxoids / administration & dosage

Substances

  • Quinazolines
  • Taxoids
  • Docetaxel
  • Irinotecan
  • ErbB Receptors
  • Protein-Tyrosine Kinases
  • Gefitinib
  • Camptothecin